Adoptive T cell therapy is a promising treatment for hematological malignancies as shown by impressive responses of anti-CD19 CAR T cells in patients with acute lymphoblastic leukemia and B cell lymphoma [37–39]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.